• 1. Enabling non-flammable Li-metal batteries via electrolyte functionalization and interface engineering?
  Jing Yu,Yu-Qi Lyu,Jiapeng Liu,Mohammed B. Effat,Junxiong Wu J. Mater. Chem. A, 2019,7, 17995-18002
• 2. Excellent electrochemical performance of LiFe0.4Mn0.6PO4 microspheres produced using a double carbon coating process?
  Yong Ping Huang,Tao Tao,Zheng Chen,Wei Han,Ying Wu,Chunjiang Kuang,Shaoxiong Zhou,Ying Chen J. Mater. Chem. A, 2014,2, 18831-18837
• 3. Evolution of calcium phosphate precipitation in hanging drop vapor diffusion by in situRaman microspectroscopy
  Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212
• 4. Embedding cyclic nitrone in mesoporous silica particles for EPR spin trapping of superoxide and other radicals?
  Eric Besson,Stéphane Gastaldi,Emily Bloch,Selma Aslan,Hakim Karoui,Olivier Ouari,Micael Hardy Analyst, 2019,144, 4194-4203
• 5. Emerging investigator series: heterogeneous reactions of sulfur dioxide on mineral dust nanoparticles: from single component to mixed components?
  Tao Wang,Yangyang Liu,Yue Deng,Hongbo Fu,Jianmin Chen Environ. Sci.: Nano, 2018,5, 1821-1833

Introduction to 5-Methoxy-1H-pyrrolo[2,3-b]pyridine-3-carboxylic acid (CAS No. 1190322-23-6)

5-Methoxy-1H-pyrrolo[2,3-b]pyridine-3-carboxylic acid, identified by its CAS number 1190322-23-6, is a heterocyclic compound that has garnered significant attention in the field of pharmaceutical chemistry and medicinal biology. This compound belongs to the pyrrolopyridine class, a structural motif known for its broad biological activity and utility in drug discovery. The presence of a methoxy group at the 5-position and a carboxylic acid moiety at the 3-position introduces unique electronic and steric properties, making it a versatile scaffold for further chemical modifications and biological evaluations.

The 5-Methoxy-1H-pyrrolo[2,3-b]pyridine-3-carboxylic acid scaffold has been extensively studied for its potential in modulating various biological pathways. Recent advancements in computational chemistry and high-throughput screening have highlighted its significance as a building block for the development of novel therapeutic agents. The compound's ability to interact with multiple targets has positioned it as a promising candidate for addressing complex diseases, including cancer, neurodegenerative disorders, and inflammatory conditions.

In the context of modern drug discovery, the 5-Methoxy-1H-pyrrolo[2,3-b]pyridine-3-carboxylic acid derivative has been explored for its pharmacokinetic and pharmacodynamic properties. Studies have demonstrated that modifications at the carboxylic acid group can enhance solubility and bioavailability, critical factors for successful drug development. Additionally, the methoxy substituent at the 5-position plays a crucial role in influencing the compound's binding affinity to biological targets. This dual functionality makes it an attractive candidate for structure-activity relationship (SAR) studies.

Recent research has also focused on the synthesis of 5-Methoxy-1H-pyrrolo[2,3-b]pyridine-3-carboxylic acid derivatives using innovative synthetic methodologies. Transition metal-catalyzed reactions and asymmetric synthesis techniques have been employed to achieve high yields and enantioselectivity. These advancements not only facilitate the production of complex derivatives but also enable the exploration of novel chemical space. The synthesis of such derivatives is often guided by computational predictions, which help in identifying optimal reaction conditions and minimizing side products.

The biological activity of 5-Methoxy-1H-pyrrolo[2,3-b]pyridine-3-carboxylic acid has been evaluated in several preclinical studies. Notably, derivatives of this compound have shown inhibitory effects on kinases and other enzymes involved in cancer progression. The carboxylic acid group serves as a hydrogen bond acceptor, enhancing interactions with target proteins, while the pyrrolopyridine core provides a rigid framework for optimal binding orientation. These features have led to the identification of several lead compounds that are currently undergoing further optimization.

Another area of interest is the exploration of 5-Methoxy-1H-pyrrolo[2,3-b]pyridine-3-carboxylic acid in treating neurodegenerative diseases such as Alzheimer's and Parkinson's. Preliminary studies suggest that certain derivatives can modulate neurotransmitter release and reduce oxidative stress in neuronal cells. The methoxy group at the 5-position appears to be particularly important in these interactions, suggesting that further modifications may enhance therapeutic efficacy while minimizing off-target effects.

The pharmacological profile of 5-Methoxy-1H-pyrrolo[2,3-b]pyridine-3-carboxylic acid also includes anti-inflammatory properties. Derivatives of this compound have been shown to inhibit inflammatory pathways by modulating cytokine production and immune cell function. This makes it a potential candidate for treating chronic inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease. The carboxylic acid group's ability to engage with hydrophilic pockets on target proteins contributes to its anti-inflammatory activity.

In conclusion, 5-Methoxy-1H-pyrrolo[2,3-b]pyridine-3-carboxylic acid (CAS No. 1190322-23-6) represents a valuable scaffold for pharmaceutical innovation. Its unique structural features and demonstrated biological activity make it a promising candidate for further development into therapeutic agents targeting various diseases. Continued research into synthetic methodologies and biological evaluations will likely uncover new applications and enhance our understanding of this compound's potential.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)